Physician profile
Stephen D Fox
NPI 1033194022
$848.21
in general payments reported to CMS, 2019-2025
15 companies · $24.00 in 2025
The $24.00 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $205 · 2021: $155 · 2023: $21.50 · 2025: $24.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $45.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $45.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $207.98 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $117.09 | 2019-2020 | |
| Amgen INC. | $116.22 | 2019-2025 | Uplizna, Parsabiv |
| Vifor Pharma, INC. | $91.00 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $66.22 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $45.09 | 2019 | |
| Aurinia Pharma U.S., INC. | $36.73 | 2021 | |
| Daiichi Sankyo INC. | $26.89 | 2019 | |
| Genzyme Corporation | $25.95 | 2019 | |
| Amag Pharmaceuticals, INC. | $24.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.39 | 2021 | |
| Baxter Healthcare | $22.36 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $19.97 | 2019 | |
| Travere Therapeutics, INC. | $13.25 | 2019 | |
| Fresenius USA Marketing, INC. | $12.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.